Arm 1 for THC

Phase-Based Progress Estimates
HIV Neurobehavioral Research Program (HNRP), San Diego, CA
THC+7 More
THC - Drug
All Sexes
What conditions do you have?

Study Summary

This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.

Eligible Conditions

  • Hiv
  • Cannabis
  • THC
  • Neuroinflammatory Disease
  • Microbiome
  • Human Immunodeficiency Virus (HIV) Infections
  • Neuroinflammatory Response

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for THC

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Change from Week 4 to Week 6

Week 6
blood-brain barrier (BBB)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for THC

Trial Design

4 Treatment Groups

Arm 2
1 of 4
CBD first, then THC
1 of 4
Arm 1
1 of 4
THC first, then CBD
1 of 4
Active Control
Experimental Treatment

100 Total Participants · 4 Treatment Groups

Primary Treatment: Arm 1 · No Placebo Group · Phase 2

Arm 1Experimental Group · 2 Interventions: THC, CBD · Intervention Types: Drug, Drug
THC first, then CBDExperimental Group · 2 Interventions: THC, CBD · Intervention Types: Drug, Drug
Arm 2ActiveComparator Group · 2 Interventions: THC, CBD · Intervention Types: Drug, Drug
CBD first, then THCActiveComparator Group · 2 Interventions: THC, CBD · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from week 4 to week 6

Trial Background

Ronald Ellis, Principal Investigator
Principal Investigator
University of California, San Diego
Closest Location: HIV Neurobehavioral Research Program (HNRP) · San Diego, CA
Photo of san diego  1Photo of san diego  2Photo of san diego  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching THC
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have the capacity to provide informed consent to a set of neuromedical assessment procedures.
You have not used cannabis in the past 6 months.
Individuals with HIV must be virally suppressed on stable ART for at least 3 months.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.